Abbott Laboratories (ABT)
Days of sales outstanding (DSO)
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
DSO | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
The provided data for Abbott Laboratories' Days of Sales Outstanding (DSO) indicates that specific figures are not available for each period from March 31, 2020, to December 31, 2024. DSO is a financial ratio that measures the average number of days a company takes to collect revenue after a sale is made. It is a crucial metric that reflects the efficiency of a company's accounts receivable management.
Without the actual DSO figures for Abbott Laboratories across the mentioned time frame, it is challenging to provide a detailed analysis of the company's collection efficiency, trend in customer credit practices, or effectiveness of its accounts receivable management. However, a high DSO may indicate potential issues with accounts receivable collection, such as lax credit policies or problems with customer payments, while a low DSO suggests efficient collection processes.
For a more comprehensive analysis of Abbott Laboratories' DSO and its implications on the company's financial performance and liquidity position, actual DSO values for the respective periods would be necessary.
Peer comparison
Dec 31, 2024
See also:
Abbott Laboratories Average Receivable Collection Period (Quarterly Data)